Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Willardiine is a naturally occurring amino acid derivative isolated from the seeds of Acacia willariana. It acts as a partial agonist at ionotropic glutamate receptors—specifically the non-NMDA subtypes AMPA and kainate receptors. These receptors are found at excitatory synapses in the central nervous system and mediate fast synaptic transmission by binding glutamate or structurally similar ligands such as willardiine. Activation of these receptors by willardiine leads to an influx of positive ions into neurons and subsequent neural depolarization. Willardiine has been primarily used as a research tool to study receptor structure and function; it is not approved for therapeutic use in any indication[1][2]. Only the (S)-isomer binds effectively to AMPA/kainate receptors[2]. Overactivation can cause neurotoxicity, but at typical research concentrations, toxicity is low[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on willardiine.